These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 32760200)

  • 1. Bile acids mediated potential functional interaction between FXR and FATP5 in the regulation of Lipid Metabolism.
    Kumari A; Pal Pathak D; Asthana S
    Int J Biol Sci; 2020; 16(13):2308-2322. PubMed ID: 32760200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities.
    Radun R; Trauner M
    Semin Liver Dis; 2021 Nov; 41(4):461-475. PubMed ID: 34289507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis.
    Doege H; Baillie RA; Ortegon AM; Tsang B; Wu Q; Punreddy S; Hirsch D; Watson N; Gimeno RE; Stahl A
    Gastroenterology; 2006 Apr; 130(4):1245-58. PubMed ID: 16618416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear bile acid signaling through the farnesoid X receptor.
    Mazuy C; Helleboid A; Staels B; Lefebvre P
    Cell Mol Life Sci; 2015 May; 72(9):1631-50. PubMed ID: 25511198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ApoB siRNA-induced liver steatosis is resistant to clearance by the loss of fatty acid transport protein 5 (Fatp5).
    Ason B; Castro-Perez J; Tep S; Stefanni A; Tadin-Strapps M; Roddy T; Hankemeier T; Hubbard B; Sachs AB; Michael Flanagan W; Kuklin NA; Mitnaul LJ
    Lipids; 2011 Nov; 46(11):991-1003. PubMed ID: 21826528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The regulation of tissue-specific farnesoid X receptor on genes and diseases involved in bile acid homeostasis.
    Xiang D; Yang J; Liu L; Yu H; Gong X; Liu D
    Biomed Pharmacother; 2023 Dec; 168():115606. PubMed ID: 37812893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism.
    Wang S; Sheng F; Zou L; Xiao J; Li P
    J Adv Res; 2021 Dec; 34():109-122. PubMed ID: 35024184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection.
    Cao Y; Xiao Y; Zhou K; Yan J; Wang P; Yan W; Cai W
    Am J Physiol Gastrointest Liver Physiol; 2019 Aug; 317(2):G108-G115. PubMed ID: 30920307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic Bile Acid Reuptake in the Rat Depends on Bile Acid Conjugation but Not on Agonistic Properties towards FXR and TGR5.
    Trammell SAJ; Svenningsen JS; Holst JJ; Gillum MP; Kuhre RE
    Molecules; 2020 May; 25(10):. PubMed ID: 32443832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Current Understanding of FXR in NAFLD: The multifaceted regulatory role of FXR and novel lead discovery for drug development.
    Tang Y; Fan Y; Wang Y; Wang D; Huang Q; Chen T; Cao X; Wen C; Shen X; Li J; You Y
    Biomed Pharmacother; 2024 Jun; 175():116658. PubMed ID: 38701562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of farnesoid X receptor and its role in bile acid metabolism.
    Chiang JYL; Ferrell JM
    Mol Cell Endocrinol; 2022 May; 548():111618. PubMed ID: 35283218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mice deleted for fatty acid transport protein 5 have defective bile acid conjugation and are protected from obesity.
    Hubbard B; Doege H; Punreddy S; Wu H; Huang X; Kaushik VK; Mozell RL; Byrnes JJ; Stricker-Krongrad A; Chou CJ; Tartaglia LA; Lodish HF; Stahl A; Gimeno RE
    Gastroenterology; 2006 Apr; 130(4):1259-69. PubMed ID: 16618417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice.
    Rao A; Kosters A; Mells JE; Zhang W; Setchell KD; Amanso AM; Wynn GM; Xu T; Keller BT; Yin H; Banton S; Jones DP; Wu H; Dawson PA; Karpen SJ
    Sci Transl Med; 2016 Sep; 8(357):357ra122. PubMed ID: 27655848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bile acids as regulators of hepatic lipid and glucose metabolism.
    Trauner M; Claudel T; Fickert P; Moustafa T; Wagner M
    Dig Dis; 2010; 28(1):220-4. PubMed ID: 20460915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tauroursodeoxycholic Acid Improves Nonalcoholic Fatty Liver Disease by Regulating Gut Microbiota and Bile Acid Metabolism.
    Wang H; Guo Y; Han W; Liang M; Xiao X; Jiang X; Yu W
    J Agric Food Chem; 2024 Sep; 72(36):20194-20210. PubMed ID: 39193771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway.
    Sun R; Yang N; Kong B; Cao B; Feng D; Yu X; Ge C; Huang J; Shen J; Wang P; Feng S; Fei F; Guo J; He J; Aa N; Chen Q; Pan Y; Schumacher JD; Yang CS; Guo GL; Aa J; Wang G
    Mol Pharmacol; 2017 Feb; 91(2):110-122. PubMed ID: 27932556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity.
    Mueller M; Thorell A; Claudel T; Jha P; Koefeler H; Lackner C; Hoesel B; Fauler G; Stojakovic T; Einarsson C; Marschall HU; Trauner M
    J Hepatol; 2015 Jun; 62(6):1398-404. PubMed ID: 25617503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individual bile acids have differential effects on bile acid signaling in mice.
    Song P; Rockwell CE; Cui JY; Klaassen CD
    Toxicol Appl Pharmacol; 2015 Feb; 283(1):57-64. PubMed ID: 25582706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic cholesterol accumulation ascribed to the activation of ileum Fxr-Fgf15 pathway inhibiting hepatic Cyp7a1 in high-fat diet-induced obesity rats.
    Duan Y; Zhang F; Yuan W; Wei Y; Wei M; Zhou Y; Yang Y; Chang Y; Wu X
    Life Sci; 2019 Sep; 232():116638. PubMed ID: 31288013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yangonin modulates lipid homeostasis, ameliorates cholestasis and cellular senescence in alcoholic liver disease via activating nuclear receptor FXR.
    Kong L; Dong R; Huang K; Wang X; Wang D; Yue N; Wang C; Sun P; Gu J; Luo H; Liu K; Wu J; Sun H; Meng Q
    Phytomedicine; 2021 Sep; 90():153629. PubMed ID: 34304130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.